247 related articles for article (PubMed ID: 36510488)
1. Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review.
Xie Z; Yang S; Deng W; Li J; Chen J
Clin Epidemiol; 2022; 14():1463-1476. PubMed ID: 36510488
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review.
Xie Z; Hu J; Gu H; Li M; Chen J
Front Endocrinol (Lausanne); 2023; 14():1244432. PubMed ID: 37701904
[TBL] [Abstract][Full Text] [Related]
3. Association of Glucagon-like Peptide 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events: A Systematic Review and Network Meta-analysis.
Vosoughi K; Atieh J; Khanna L; Khoshbin K; Prokop LJ; Davitkov P; Murad MH; Camilleri M
EClinicalMedicine; 2021 Dec; 42():101213. PubMed ID: 34877513
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: A network meta-analysis.
Xia L; Shen T; Dong W; Su F; Wang J; Wang Q; Niu S; Fang Y
Diabetes Res Clin Pract; 2021 Jul; 177():108904. PubMed ID: 34102249
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis.
Alhindi Y; Avery A
Contemp Clin Trials Commun; 2022 Aug; 28():100944. PubMed ID: 35812819
[TBL] [Abstract][Full Text] [Related]
6. The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.
Guo X; Zhou Z; Lyu X; Xu H; Zhu H; Pan H; Wang L; Yang H; Gong F
Horm Metab Res; 2022 Jul; 54(7):458-471. PubMed ID: 35512849
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).
Capehorn MS; Catarig AM; Furberg JK; Janez A; Price HC; Tadayon S; Vergès B; Marre M
Diabetes Metab; 2020 Apr; 46(2):100-109. PubMed ID: 31539622
[TBL] [Abstract][Full Text] [Related]
8. Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes.
Zaazouee MS; Hamdallah A; Helmy SK; Hasabo EA; Sayed AK; Gbreel MI; Elmegeed AA; Aladwan H; Elshanbary AA; Abdel-Aziz W; Elshahawy IM; Rabie S; Elkady S; Ali AS; Ragab KM; Nourelden AZ
Diabetes Metab Syndr; 2022 Jun; 16(6):102511. PubMed ID: 35623229
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
O'Neil PM; Birkenfeld AL; McGowan B; Mosenzon O; Pedersen SD; Wharton S; Carson CG; Jepsen CH; Kabisch M; Wilding JPH
Lancet; 2018 Aug; 392(10148):637-649. PubMed ID: 30122305
[TBL] [Abstract][Full Text] [Related]
10. Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis.
Alsugair HA; Alshugair IF; Alharbi TJ; Bin Rsheed AM; Tourkmani AM; Al-Madani W
Healthcare (Basel); 2021 Aug; 9(9):. PubMed ID: 34574899
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Luo Q; Wei R; Cai Y; Zhao Q; Liu Y; Liu WJ
Front Med (Lausanne); 2022; 9():793203. PubMed ID: 35280867
[TBL] [Abstract][Full Text] [Related]
13. Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review.
Deng Y; Park A; Zhu L; Xie W; Pan CQ
Ther Adv Chronic Dis; 2022; 13():20406223221108064. PubMed ID: 35813188
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial.
Qin W; Yang J; Deng C; Ruan Q; Duan K
Diabetes Obes Metab; 2024 Mar; 26(3):911-923. PubMed ID: 38016699
[TBL] [Abstract][Full Text] [Related]
15. Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis.
Avgerinos I; Michailidis T; Liakos A; Karagiannis T; Matthews DR; Tsapas A; Bekiari E
Diabetes Obes Metab; 2020 Mar; 22(3):335-345. PubMed ID: 31637820
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis.
Li H; Yu G; Huang Q; Yang B; Nie J; Liu Y; Tu X
Biomed Pharmacother; 2024 Feb; 171():116150. PubMed ID: 38242040
[TBL] [Abstract][Full Text] [Related]
17. A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.
Nauck MA; Petrie JR; Sesti G; Mannucci E; Courrèges JP; Lindegaard ML; Jensen CB; Atkin SL;
Diabetes Care; 2016 Feb; 39(2):231-41. PubMed ID: 26358288
[TBL] [Abstract][Full Text] [Related]
18. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
Johansen P; Sandberg A; Capehorn M
Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
[TBL] [Abstract][Full Text] [Related]
19. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
[TBL] [Abstract][Full Text] [Related]
20. The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis.
Li X; Qie S; Wang X; Zheng Y; Liu Y; Liu G
Endocrine; 2018 Dec; 62(3):535-545. PubMed ID: 30101378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
